EWA
PTGX icon

EverSource Wealth Advisors’s Protagonist Therapeutics PTGX Stock Holding History

EverSource Wealth Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63K Sell
514
-397
-44% -$41.5K ﹤0.01% 1627
2026
Q1 		$96K Buy
911
+352
+63% +$31.2K ﹤0.01% 1453
2025
Q4 		$48.8K Buy
559
+19
+4% +$1.55K ﹤0.01% 1766
2025
Q3 		$35.9K Buy
540
+314
+139% +$17.8K ﹤0.01% 1948
2025
Q2 		$12.5K Buy
226
+137
+154% +$6.58K ﹤0.01% 2659
2025
Q1 		$4.3K Buy
89
+79
+790% +$3.31K ﹤0.01% 2568
2024
Q4 		$386 Buy
+10
New +$436 ﹤0.01% 3278

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

EverSource Wealth Advisors's PTGX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Protagonist Therapeutics (PTGX) stake by 44% in Q2 2026, selling an estimated $41.5K and leaving 514 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #1627.

EverSource Wealth Advisors first reported a position in PTGX in Q4 2024 and has held it in 7 quarters since. The position peaked at $96K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • EverSource Wealth Advisors held 514 shares of Protagonist Therapeutics worth $63K as of Q2 2026.
  • EverSource Wealth Advisors sold 397 Protagonist Therapeutics shares in Q2 2026, an estimated $41.5K.
  • Protagonist Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1627 holding.
  • EverSource Wealth Advisors first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • EverSource Wealth Advisors's Protagonist Therapeutics position peaked at $96K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.